Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.
Renier Brentjens, MD, PhD
Advertisement
Articles by Renier Brentjens, MD, PhD
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential for chimeric antigen receptor therapy (CAR) T-cell therapy in solid tumors.
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses challenges facing chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for CAR T-cell therapy.
Advertisement
Latest Updated Articles
Dr. Brentjens on Research Beyond CD19 in CAR T-Cell TherapyPublished: January 5th 2018 | Updated:
Dr. Brentjens on Obstacles with CAR T-Cell Therapy in Hematologic MalignanciesPublished: January 17th 2018 | Updated:
Dr. Brentjens Discusses Potential for CAR T-Cell Therapy in Solid TumorsPublished: January 25th 2018 | Updated:
Dr. Brentjens Discusses Toxicities Associated With CAR T-Cell TherapyPublished: February 5th 2018 | Updated:
Dr. Brentjens Discusses the Goal of Armored CAR T CellsPublished: March 9th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
5